🇺🇸 FDA
Pipeline program

Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

CTX001-111

Phase 3 small_molecule active

Quick answer

Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR for Transfusion-dependent β-thalassemia (TDT) is a Phase 3 program (small_molecule) at Vertex Pharmaceuticals (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Vertex Pharmaceuticals (Ireland) Limited
Indication
Transfusion-dependent β-thalassemia (TDT)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials